Celgene-backed CRISPR company emerges with $68M Series A – BioPharma Dive
Endpoints News |
Celgene-backed CRISPR company emerges with $68M Series A
BioPharma Dive After an 18-month stealth period, Repare Therapeutics has burst into the limelight with a $68 million Series A funding, a CRISPR-enabled synthetic lethality drug discovery platform and a pipeline of three preclinical programs targeting “vulnerabilities … CRISPR crew’s lab test spotlights lead program in sickle cell disease, beta-thalassemiaEndpoints News Analyst Recommendations And Earnings Forecast: CRISPR Therapeutics AG (CRSP), JD.com, Inc. (JD)Post Analyst Crispr Theraptc (CRSP) Given $26.75 Consensus Target Price by BrokeragesBNB Daily (blog) Stock Observer –BBNS all 11 news articles » |
STAT |
Early Data for bluebird bio Gene–Therapy Candidate Show Some Promise
Genetic Engineering & Biotechnology News bluebird bio today disclosed its first data, including some promising results, from a pair of clinical studies assessing its LentiGlobin™ gene therapy candidate—including a Phase III study that followed a change in its manufacturing process. In the … Bluebird Bio’s gene therapy for blood disorders yields some impressive results ― but also raises questionsSTAT Bluebird Reports Early Results From Upgraded Gene TherapyXconomy Bluebird bio steps up with a promising snapshot of its gene therapy upgradeEndpoints News FierceBiotech –Business Wire (press release) –StreetInsider.com all 10 news articles » |
Medscape |
Immunotherapy: New Era for NSCLC Management
Medscape It is not often that “a new standard of care” or “remarkable” are bandied about to describe study results for novel compounds, but this is exactly what happened when trial data on immunotherapies for lung cancer were released last fall. |
Medscape |
Immunotherapy: New Era for NSCLC Management
Medscape It is not often that “a new standard of care” or “remarkable” are bandied about to describe study results for novel compounds, but this is exactly what happened when trial data on immunotherapies for lung cancer were released last fall. |
|
Focused Ultrasound Foundation, Cancer Research Institute partner to advance immunotherapy research
Healio Our goal at Cancer Research Institute is to accelerate the field of cancer immunotherapy, and we believe that focused ultrasound is a valuable tool that could increase efficacy.” Through the partnership, the organizations will establish a joint fund to … |
ALS News Today |
Israel’s BrainStorm Receives $2.1 Million Grant to Support Development of Stem–Cell Therapy NurOwn to Treat ALS
ALS News Today NurOwn was developed by Tel Aviv University professors Dani Offen and the late Eldad Melamed. NurOwn builds on research developing mesenchymal stem cells (MSCs) as a treatment for human diseases. MSCs are multipotent precursor cells that exist in … |
ALS News Today |
Israel’s BrainStorm Receives $2.1 Million Grant to Support Development of Stem–Cell Therapy NurOwn to Treat ALS
ALS News Today NurOwn was developed by Tel Aviv University professors Dani Offen and the late Eldad Melamed. NurOwn builds on research developing mesenchymal stem cells (MSCs) as a treatment for human diseases. MSCs are multipotent precursor cells that exist in … |
FierceBiotech |
Novartis-backed GenSight gets cash for gene therapy launch
FierceBiotech GenSight Biologics has raised (PDF) €22.5 million ($25.2 million) to prepare to bring gene therapy GS010 to market in the U.S. and Europe. The financing gives the Novartis-backed biotech enough cash to deliver data from two phase 3 trials next year and … French Biotech Raises Over €22M to Launch a Gene Therapy to Restore SightLabiotech.eu (blog) |